A
Andreas Engert
Researcher at University of Cologne
Publications - 741
Citations - 29653
Andreas Engert is an academic researcher from University of Cologne. The author has contributed to research in topics: Lymphoma & BEACOPP. The author has an hindex of 84, co-authored 703 publications receiving 26839 citations. Previous affiliations of Andreas Engert include Medarex.
Papers
More filters
Journal ArticleDOI
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier,Corinne Haioun,Nicolas Ketterer,Andreas Engert,H. Tilly,David D.F. Ma,Peter Johnson,Andrew Lister,M. Feuring Buske,John Radford,R. Capdeville,Volker Diehl,Felix Reyes +12 more
TL;DR: In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity and should be tested in combination with chemotherapy in such patients.
Journal ArticleDOI
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes,Armando Santoro,Margaret A. Shipp,Pier Luigi Zinzani,John M. Timmerman,Stephen M. Ansell,Philippe Armand,Michelle A. Fanale,Voravit Ratanatharathorn,John Kuruvilla,Jonathon B. Cohen,Graham P. Collins,Kerry J. Savage,Marek Trneny,Kazunobu Kato,Benedetto Farsaci,Susan M. Parker,Scott J. Rodig,Margaretha G.M. Roemer,Azra H. Ligon,Andreas Engert +20 more
TL;DR: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin, and might be a new treatment option for a patient population with a high unmet need.
Journal ArticleDOI
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
TL;DR: E efficacy in patients with relapsed fludarabine-resistant B-CLL was poor and different infusion schedules and/or combination regimens with chemotherapeutic drugs to reduce tumor burden before treatment with rituximab will have to be evaluated.
Journal ArticleDOI
Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients
Julia Bohlius,Jayne S. Wilson,Jerome Seidenfeld,Margaret Piper,Guido Schwarzer,Josie Sandercock,Sven Trelle,Olaf Weingart,Susan Bayliss,Benjamin Djulbegovic,Charles L. Bennett,Simon Langensiepen,Chris Hyde,Andreas Engert +13 more
TL;DR: Caution is advised when using epoet in or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events.
Journal ArticleDOI
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert,Heinz Haverkamp,Carsten Kobe,Jana Markova,Christoph Renner,A. D. Ho,Josée M. Zijlstra,Zdenek Kral,Michael Fuchs,Michael Hallek,Lothar Kanz,Hartmut Döhner,Bernd Dörken,Nicole Engel,Max S. Topp,Susanne Klutmann,Holger Amthauer,Andreas Bockisch,Regine Kluge,Clemens Kratochwil,Otmar Schober,Richard Greil,Reinhard Andreesen,Michael Kneba,Michael Pfreundschuh,Harald Stein,Hans Theodor Eich,Rolf-Peter Müller,Markus Dietlein,Peter Borchmann,Volker Diehl +30 more
TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.